New lanes on I-4 alleviate backups from Polk County to Osceola County
'I drive on I-4 daily,' said Chad Jones, who works as a sales representative for a roofing company. 'It was a parking lot to say the least, a lot of congestion.'
Orange juice truck flips over in Bradenton
He said he can tell the traffic flow has improved this week.
'You can notice more of a flow. It's not as bumper to bumper all the time,' Jones said.
In recent days, the Florida Department of Transportation opened a fourth lane on each side of I-4 between U.S. 27 and World Drive, a $27 million project.
It is considered a first step in the $3.4 billion Moving I-4 Forward program.
'Seeing blue on your GPS, that's something that drivers have not seen in that area for a long time. So to finally see it, that shows that it's working, it's a sign of success,' said Matthew Richardson, director of communications for the Moving I-4 Forward program.
Richardson said the 'congestion relief lanes' were completed eight months ahead of schedule.
Along with updates to interchanges on I-4, the state is also planning 'Project 3,' which will extend Orlando-area paid express lanes into Polk County.
A completion date is not being made public yet but work on the express lanes is set to begin in 2026.
'Those express lanes are a proven method that has helped to reduce congestion along I-4 and also gives drivers an option on how to best get to their destination quicker,' Richardson said. 'The goal is to have a continuous connectivity throughout Seminole, Orange and into Polk County.'
The state is also working on alternate routes, including the Central Polk Parkway East.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the biotechnology company's vaccines. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and Matrix-M adjuvant technology. The Maryland-based company has an approved COVID-19 vaccine, Nuvaxovid, which is being commercialized globally through partnerships, including a major agreement with Sanofi. Currently, the company is expanding its product reach for emerging infectious disease prevention. On May 19, 2025, Novavax, Inc. (NASDAQ:NVAX) announced that it had received U.S. FDA Biologics License Application (BLA) approval for Nuvaxovid™, a recombinant protein-based, non-mRNA COVID-19 vaccine. The BLA approval triggered a $175 million milestone payment from Sanofi. Later, for select markets, Novavax, Inc. (NASDAQ:NVAX) has completed the transition of Nuvaxovid™ commercial leadership to Sanofi for the 2025-2026 COVID-19 vaccination season. By Q4 2025, the marketing authorization transfers to Sanofi for the U.S. and EU markets will be completed, which will result in an additional $50 million in combined milestones. Additionally, in June 2025, initial cohort data from a Phase 3 trial for Novavax's COVID-19-Influenza-Combination (CIC) and stand-alone influenza vaccine candidates showed significant immune responses, with T-cell responses numerically higher than the comparator Fluzone HD arm. With the results suggesting increased duration of protection, the company is discussing potential partnerships for these late-stage assets. Novavax, Inc. (NASDAQ:NVAX)'s 29.12% short float signals heavy bearish sentiment. With it, the company is up on the stage for a sharp rebound with slight positive market sentiment shifts. While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
40 minutes ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Yahoo
an hour ago
- Yahoo
Research Solutions to Present and Host 1x1 Investor Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 27th
HENDERSON, Nev., Aug. 20, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading AI-powered research workflow platform, announced that management will present at the Midwest IDEAS Investor Conference on Wednesday August 27, 2025 at The InterContinental in Chicago, IL. The company's presentation is scheduled to begin at 9:15am CT. The presentation is webcast and can be accessed through the conference host's main website: Qualified investors interested in participating or learning more about the IDEAS conferences, please contact Lacey Wesley at (817) 769 -2373 or lWesley@ About Research SolutionsResearch Solutions, Inc. (NASDAQ: RSSS) provides cloud-based technologies to streamline the process of obtaining, managing, and creating intellectual property. Founded in 2006 as Reprints Desk, the company was a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical companies, prestigious universities, and emerging businesses rely on Article Galaxy, the company's SaaS research platform, to streamline access to the latest scientific research and data with 24/7 customer support. For more information and details, please visit View original content to download multimedia: SOURCE Research Solutions, Inc.
